Among these inhibitors, Erlotinib was approved in 2004 for all NSCLC patients (wild type EGFR) and in 2014 for advanced NSCLC patients (mutant EGFR) to increase survival in the U.S. Food & Drug Administration (FDA) [8]. Here, EGFR is linked to non-small cell lung carcinoma.